Soohyun Kim is President of Corporate Affairs for YbdY. In this role, he is responsible for shaping YbdY’s policy on scientific research and discovery of target molecules for therapies. He utilized his extensive background in cytokine biology, biotechnology, phamaceutical and business. Dr. Kim has served as a head of the department of Biomedical Science and Technology in Konkuk University since 2007. Dr. Kim discovered Interleukin-18 binding protein in 1999 and Interleukin-32 in 2005 that are important molecules in cytokine related therapies. Currently, Dr Kim and YbdY’s research group are searching new novel cytokine-related molecules for the future cytokine therapies.
